Literature DB >> 18549931

Parvovirus B19 infection and systemic lupus erythematosus: Activation of an aberrant pathway?

Spyros Aslanidis1, Athina Pyrpasopoulou, Kostas Kontotasios, Stella Doumas, Chryssanthos Zamboulis.   

Abstract

Parvovirus B19 infection has been associated with a variety of rheumatic manifestations/diseases, mainly rheumatoid arthritis, vasculitis and systemic lupus erythematosus (SLE). B19 infection may simulate both clinical and laboratory features of SLE, presenting either as a potential first time diagnosis of SLE or as an exacerbation of previously established disease. The similarities in both clinical and serological features of parvovirus infection and SLE at presentation may hinder the differential diagnosis between these two conditions. Hence, parvovirus B19 infection mimicking SLE usually fulfils <4 ACR criteria for SLE, rarely includes cardiac or renal involvement or presents with haemolytic anaemia, and is usually associated with short-lived, low titers of autoantibodies. Rarely, cases of multisystemic involvement solely attributed to a recent parvovirus B19 infection have been reported, rendering early accurate diagnosis of particular importance and justifying the screening for evidence of parvovirus B19 involvement in newly diagnosed cases of SLE, especially the ones with abrupt onset of symptoms along with cases of SLE flares. This review describes basic features of parvovirus B19 structure and pathogenicity and expands on the parvo-associated auto-immune manifestations particularly in relation to SLE-mimicking or SLE-triggering reported cases. The proposed mechanisms for viral-induced pathologic autoimmunity are discussed with emphasis on emerging data regarding the aberrant expression and localization of autoantigens and their potential implication in alternatively activated immunological cascades.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18549931     DOI: 10.1016/j.ejim.2007.09.013

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  22 in total

Review 1.  The Clinical Relevance of Anti-DFS70 Autoantibodies.

Authors:  Karsten Conrad; Nadja Röber; Luis E C Andrade; Michael Mahler
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

2.  Secondary neuropsychiatric manifestations caused by Epstein-Barr virus encephalitis in a new onset systemic lupus erythematosus patient.

Authors:  Chen Hongbo; Ma Hongzhen; He Lingzhi; Xu Maosheng; Chen Mei
Journal:  Rheumatol Int       Date:  2011-05-24       Impact factor: 2.631

Review 3.  Infections and systemic lupus erythematosus.

Authors:  S Esposito; S Bosis; M Semino; D Rigante
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-09       Impact factor: 3.267

4.  Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus.

Authors:  Leomar D C Lyrio; Maria Fernanda R Grassi; Iuri U Santana; Viviana G Olavarria; Aline do N Gomes; Licia CostaPinto; Rone Peterson C Oliveira; Rita de Cássia R Aquino; Mittermayer B Santiago
Journal:  Rheumatol Int       Date:  2012-03-27       Impact factor: 2.631

Review 5.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 6.  Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus.

Authors:  Alexandros P Grammatikos; George C Tsokos
Journal:  Trends Mol Med       Date:  2011-12-15       Impact factor: 11.951

Review 7.  Pathogenesis of human systemic lupus erythematosus: recent advances.

Authors:  José C Crispín; Stamatis-Nick C Liossis; Katalin Kis-Toth; Linda A Lieberman; Vasileios C Kyttaris; Yuang-Taung Juang; George C Tsokos
Journal:  Trends Mol Med       Date:  2010-02-04       Impact factor: 11.951

Review 8.  The Expanding Role of Natural Killer Cells in Type 1 Diabetes and Immunotherapy.

Authors:  Chris Fraker; Allison L Bayer
Journal:  Curr Diab Rep       Date:  2016-11       Impact factor: 4.810

9.  Does parvovirus infection have a role in systemic lupus erythematosus?

Authors:  Tami Hod; Giselle Zandman-Goddard; Pnina Langevitz; Hagit Rudnic; Zehava Grossman; Pnina Rotman-Pikielny; Yair Levy
Journal:  Immunol Res       Date:  2017-04       Impact factor: 4.505

10.  Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors.

Authors:  C Reinheimer; R Allwinn; H W Doerr; M Wittek
Journal:  Infection       Date:  2010-06-17       Impact factor: 7.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.